OTR3 is a leading biotechnology company
in a new branch of Regenerating Medicine:
OTR3® is a biotechnology company founded by Professors Denis Barritault and Jean-Pierre Caruelle† from the University of Paris-East Créteil in 2000, laureates of the French national competition for the creation of the best innovative company. Known for their pioneering work on growth factors – the discovery of FGF, HARP/PTN – they invented the RGTA® Technology (ReGeneraTing Agents), a new therapeutic class in regenerative medicine.
The RGTA® Technology is patent protected worldwide.
OTR3® has currently one CE marked medical device CACIPLIQ20® on the market.
OTR3® is the recipient of a H2020 SME Instrument Phase 2 funding to develop a new therapeutic product for the treatment of ischemic stroke.
The goal of OTR3® is to continue exploring the potential of the RGTA® Technology, developing new indications and innovative healthcare products. Our expansion relies on extensive cutting-edge research and development that will allow us to bring to patients innovative therapeutic solutions that really make a difference.
OTR3® focuses on extending its portfolio to a wider range of new products, each based on RGTA® molecules tailored for the treatment of specific diseases.
OTR3® doesn’t sell directly its products to the patient. The commercialisation of our products is licensed out to a network of pharmaceutical companies throughout the world.
OTR3®‘s multidisciplinary team is fully dedicated to bringing new products that really matter to answer the need of patients.
A steering board, composed of recognised professionals, assists OTR3’s team providing scientific, business and strategic advice.